- Home
- GRDN vs TNGX Comparison
GRDN vs TNGX Comparison
Compare GRDN & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRDN | TNGX |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | GRDN | TNGX |
|---|---|---|
| Price | $30.71 | $11.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $33.33 | $13.00 |
| AVG Volume (30 Days) | 276.6K | ★ 3.4M |
| Earning Date | 11-10-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,389,638,000.00 | $66,501,000.00 |
| Revenue This Year | $19.50 | $52.80 |
| Revenue Next Year | $0.48 | N/A |
| P/E Ratio | $108.55 | ★ N/A |
| Revenue Growth | 18.68 | ★ 53.29 |
| 52 Week Low | $17.78 | $1.03 |
| 52 Week High | $37.43 | $13.46 |
Technical Indicators
Market Signals| Indicator | GRDN | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 55.76 |
| Support Level | $29.07 | $11.41 |
| Resistance Level | $31.11 | $12.30 |
| Average True Range (ATR) | 1.51 | 0.99 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 76.44 | 48.70 |
Price Performance
Historical ComparisonAbout GRDN Guardian Pharmacy Services Inc.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.